↓ Skip to main content

Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials

Overview of attention for article published in Diabetology & Metabolic Syndrome, October 2009
Altmetric Badge

Mentioned by

twitter
1 X user
reddit
1 Redditor

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
57 Mendeley
connotea
1 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials
Published in
Diabetology & Metabolic Syndrome, October 2009
DOI 10.1186/1758-5996-1-19
Pubmed ID
Authors

Carlos Eduardo Barra Couri, Júlio César Voltarelli

Abstract

Stem cell therapy is one of the most promising treatments for the near future. It is expected that this kind of therapy can ameliorate or even reverse some diseases. With regard to type 1 diabetes, studies analyzing the therapeutic effects of stem cells in humans began in 2003 in the Hospital das Clínicas of the Faculty of Medicine of Ribeirão Preto - SP USP, Brazil, and since then other centers in different countries started to randomize patients in their clinical trials. Herein we summarize recent data about beta cell regeneration, different ways of immune intervention and what is being employed in type 1 diabetic patients with regard to stem cell repertoire to promote regeneration and/or preservation of beta cell mass.The Diabetes Control and Complications Trial (DCCT) was a 7-year longitudinal study that demonstrated the importance of the intensive insulin therapy when compared to conventional treatment in the development of chronic complications in patients with type 1 diabetes mellitus (T1DM). This study also demonstrated another important issue: there is a reverse relationship between C-peptide levels (endogenous indicator of insulin secretion) chronic complications - that is, the higher the C-peptide levels, the lower the incidence of nephropathy, retinopathy and hypoglycemia. From such data, beta cell preservation has become an additional target in the management of T1DM 1.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Nepal 1 2%
Brazil 1 2%
India 1 2%
Belgium 1 2%
United States 1 2%
Unknown 52 91%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 23%
Student > Master 9 16%
Student > Bachelor 6 11%
Student > Ph. D. Student 5 9%
Student > Postgraduate 5 9%
Other 12 21%
Unknown 7 12%
Readers by discipline Count As %
Medicine and Dentistry 17 30%
Agricultural and Biological Sciences 17 30%
Engineering 3 5%
Biochemistry, Genetics and Molecular Biology 2 4%
Immunology and Microbiology 1 2%
Other 6 11%
Unknown 11 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 March 2014.
All research outputs
#14,724,943
of 22,663,150 outputs
Outputs from Diabetology & Metabolic Syndrome
#335
of 656 outputs
Outputs of similar age
#77,136
of 93,246 outputs
Outputs of similar age from Diabetology & Metabolic Syndrome
#5
of 6 outputs
Altmetric has tracked 22,663,150 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 656 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 93,246 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.